131 related articles for article (PubMed ID: 19752749)
1. Development of an Escherichia coli expressing listeriolysin-O vaccine against Wilms tumor gene 1-expressing tumors.
Dai MS; Nitcheu-Tefit J; Alcock S; Ramirez-Jimenez F; Chao TY; Baril P; Rocha M; Brett SJ; Stauss HJ; Vassaux G
J Immunother; 2009 Oct; 32(8):845-55. PubMed ID: 19752749
[TBL] [Abstract][Full Text] [Related]
2. Listeriolysin O expressed in a bacterial vaccine suppresses CD4+CD25high regulatory T cell function in vivo.
Nitcheu-Tefit J; Dai MS; Critchley-Thorne RJ; Ramirez-Jimenez F; Xu M; Conchon S; Ferry N; Stauss HJ; Vassaux G
J Immunol; 2007 Aug; 179(3):1532-41. PubMed ID: 17641019
[TBL] [Abstract][Full Text] [Related]
3. High efficacy of a Listeria-based vaccine against metastatic breast cancer reveals a dual mode of action.
Kim SH; Castro F; Paterson Y; Gravekamp C
Cancer Res; 2009 Jul; 69(14):5860-6. PubMed ID: 19584282
[TBL] [Abstract][Full Text] [Related]
4. Mucosal vaccine using CTL epitope-pulsed dendritic cell confers protection for intracellular pathogen.
Ozawa Y; Suda T; Nagata T; Hashimoto D; Nakamura Y; Enomoto N; Inui N; Koide Y; Nakamura H; Chida K
Am J Respir Cell Mol Biol; 2009 Oct; 41(4):440-8. PubMed ID: 19202004
[TBL] [Abstract][Full Text] [Related]
5. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
6. Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: Its utility in cytotoxic T lymphocyte-inducing DNA vaccine.
Sun X; Provoda C; Lee KD
J Control Release; 2010 Dec; 148(2):219-25. PubMed ID: 20620181
[TBL] [Abstract][Full Text] [Related]
7. Delivery of class I and class II MHC-restricted T-cell epitopes of listeriolysin of Listeria monocytogenes by attenuated Salmonella.
Verma NK; Ziegler HK; Wilson M; Khan M; Safley S; Stocker BA; Schoolnik GK
Vaccine; 1995 Feb; 13(2):142-50. PubMed ID: 7625107
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
Sewell DA; Shahabi V; Gunn GR; Pan ZK; Dominiecki ME; Paterson Y
Cancer Res; 2004 Dec; 64(24):8821-5. PubMed ID: 15604239
[TBL] [Abstract][Full Text] [Related]
9. Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.
Singh R; Dominiecki ME; Jaffee EM; Paterson Y
J Immunol; 2005 Sep; 175(6):3663-73. PubMed ID: 16148111
[TBL] [Abstract][Full Text] [Related]
10. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16.
Gunn GR; Zubair A; Peters C; Pan ZK; Wu TC; Paterson Y
J Immunol; 2001 Dec; 167(11):6471-9. PubMed ID: 11714814
[TBL] [Abstract][Full Text] [Related]
11. An in silico DNA vaccine against Listeria monocytogenes.
Jahangiri A; Rasooli I; Gargari SL; Owlia P; Rahbar MR; Amani J; Khalili S
Vaccine; 2011 Sep; 29(40):6948-58. PubMed ID: 21791233
[TBL] [Abstract][Full Text] [Related]
12. A gold glyco-nanoparticle carrying a Listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection.
Rodriguez-Del Rio E; Marradi M; Calderon-Gonzalez R; Frande-Cabanes E; Penadés S; Petrovsky N; Alvarez-Dominguez C
Vaccine; 2015 Mar; 33(12):1465-73. PubMed ID: 25659269
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy.
Peng X; Treml J; Paterson Y
Cancer Immunol Immunother; 2007 Jun; 56(6):797-806. PubMed ID: 17102978
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic-T-lymphocyte responses to epitopes of listeriolysin O and p60 following infection with Listeria monocytogenes.
Bouwer HG; Hinrichs DJ
Infect Immun; 1996 Jul; 64(7):2515-22. PubMed ID: 8698474
[TBL] [Abstract][Full Text] [Related]
15. Listeriolysin o is strongly immunogenic independently of its cytotoxic activity.
Carrero JA; Vivanco-Cid H; Unanue ER
PLoS One; 2012; 7(3):e32310. PubMed ID: 22403645
[TBL] [Abstract][Full Text] [Related]
16. Recombinant E. coli efficiently delivers antigen and maturation signals to human dendritic cells: presentation of MART1 to CD8+ T cells.
Radford KJ; Jackson AM; Wang JH; Vassaux G; Lemoine NR
Int J Cancer; 2003 Jul; 105(6):811-9. PubMed ID: 12767067
[TBL] [Abstract][Full Text] [Related]
17. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM
Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755
[TBL] [Abstract][Full Text] [Related]
18. Listeriolysin O is an improved protein carrier for lymphoma immunoglobulin idiotype and provides systemic protection against 38C13 lymphoma.
Neeson P; Pan ZK; Paterson Y
Cancer Immunol Immunother; 2008 Apr; 57(4):493-505. PubMed ID: 17876582
[TBL] [Abstract][Full Text] [Related]
19. Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer.
Dai MS; Vassaux G; Xu M; You RI; Hsieh YF; Ouisse LH; Lo KY; Sytwu HK; Chao TY
Vaccine; 2012 Nov; 30(48):6903-11. PubMed ID: 22982404
[TBL] [Abstract][Full Text] [Related]
20. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection.
Mandal M; Lee KD
Biochim Biophys Acta; 2002 Jun; 1563(1-2):7-17. PubMed ID: 12007619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
